Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas.
Simona CorsoFilippo PietrantonioMaria ApicellaCristina MiglioreDaniela ConticelliAnnalisa PetrelliLaura D'ErricoStefania DurandoDaniel Moya-RullSara Erika BellomoStefano UghettoMaurizio DegiuliRossella ReddavidUberto FumagalliStefano De PascaleGiovanni SgroiEmanuele RausaGian Luca BaiocchiSarah MolfinoGiovanni De ManzoniMaria BencivengaSalvatore SienaAndrea Sartore-BianchiFederica MoranoSalvatore CoralloMichele PrisciandaroMaria Di BartolomeoAnnunziata GloghiniSilvia MarsoniAntonino SottileAnna SapinoCaterina MarchioAsa Dahle-SmithZofia MiedzybrodzkaJessica LeeSiraj M AliJeffery S RossBrian M AlexanderVincent A MillerRussell PettyAlexa B SchrockSilvia GiordanoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
This study underscores EGFR as a potential therapeutic target in gastric cancer and identifies the combination of an EGFR TKI and a mAb as an effective therapeutic approach. Finally, it recognizes mTOR pathway activation as a novel mechanism of primary resistance that can be overcome by the combination of EGFR and mTOR inhibitors.See related commentary by Openshaw et al., p. 2964.